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Introduction
Macroautophagy (referred to hereafter as autophagy) is a self-
cannibalization process involving sequestration of cell structures 
in double-membraned organelles, called autophagosomes.1 This 
is followed by fusion of autophagosomes with lysosomes and for-
mation of autolysosomes in which internal content is degraded 
by acidic lysosomal hydrolases. The physiological role of auto-
phagy is to remove long-lived proteins and damaged organelles, 
but when it is extensive, activated inappropriately or in cells 
in the present study, we report that compound c, an inhibitor of a key intracellular energy sensor AMP-activated protein 
kinase (AMPK), can induce autophagy in cancer cells. The induction of autophagy in U251 human glioma cell line was 
demonstrated by acridine orange staining of intracellular acidic vesicles, Beclin 1 induction, p62 decrease and conversion 
of Lc3-i to autophagosome-associated Lc3-ii in the presence of proteolysis inhibitors. The presence of autophagosome-
like vesicles was confirmed by transmission electron microscopy. compound c-mediated inhibition of AMPK and raptor 
in U251 cells was associated with paradoxical decrease in phosphorylation of AMPK/raptor-repressed mTOR, a major 
negative regulator of autophagy, and its downstream target p70s6K. The phosphorylation of an mTOR activator Akt 
and the Pi3K-activating kinase src was also impaired in compound c-treated cells. The siRNA-mediated AMPK silencing 
did not reduce the activity of the Akt/mTOR/p70s6K pathway and AMPK activators metformin and AicAR failed to 
block compound c-induced autophagy. Autophagy inhibitors bafilomycin and chloroquine significantly increased 
the cytotoxicity of compound c towards U251 cells, as confirmed by increase in lactate dehydrogenase release, DNA 
fragmentation and caspase-3 activation. similar effects of compound c were also observed in c6 rat glioma, L929 mouse 
fibrosarcoma and B16 mouse melanoma cell lines. since compound c has previously been reported to suppress AMPK-
dependent autophagy in different cell types, our findings suggest that the effects of compound c on autophagy might 
be dose-, cell type- and/or context-dependent. By demonstrating the ability of compound c to induce autophagic 
response in cancer cells via AMPK inhibition-independent downregulation of Akt/mTOR pathway, our results warrant 
caution when using compound c to inhibit AMPK-dependent cellular responses, but also support further exploration of 
compound c and related molecules as potential anticancer agents.
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which are unable to die by apoptosis, autophagy acts as an alter-
native cell-death pathway called programmed cell death type 
II.2,3 Induction of autophagy by hypoxia or anticancer agents 
such as arsenic trioxide, temozolomide or fenretinide, appears 
to be deleterious for tumor cells4-7 and autophagy-deficient mice 
are more susceptible to tumorigenesis.8 Accordingly, autophagy 
has been proposed as a “magic bullet” in fighting apoptosis-
resistant cancers.9 On the other hand, a large body of evidence 
indicates that autophagy can also act as a survival mechanism 
that provides energy during metabolic stress and protects cancer 
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cells confirmed that compound C caused both dose- and time-
dependent increase in red/green (FL3/FL1) fluorescence ratio 
(Fig. 1B). Ultrastructural TEM analysis (Fig. 1C) was consis-
tent with the induction of autophagy by compound C, showing 
an extensive cytoplasmic vacuolization (middle part) with many 
autolysosome-like vesicles containing cellular debris (right part). 
An immunoblot analysis revealed a time-dependent conversion of 
microtubule-associated protein 1 light-chain 3 (LC3)-I isoform 
to autophagosome-associated LC3-II, as well as an increase in the 
expression of the pro-autophagic protein Beclin 1 in compound 
C-treated U251 cells (Fig. 1D). However, Beclin 1 increase is 
not specific for autophagy induction, as it can also play a role in 
apoptosis,40 and the increase in LC3-II may also occur as a conse-
quence of reduced autophagic proteolysis.41 Therefore, we assessed 
the influence of compound C on LC3-II levels in the presence of 
lysosomal acidification blockers that inhibit proteolysis: bafilo-
mycin A1, chloroquine and ammonium chloride. The concentra-
tions of proteolysis inhibitors saturating for LC3-II increase were 
determined in preliminary experiments (data not shown). While 
proteolysis inhibition expectedly increased LC3-II levels in U251 
cells, treatment with compound C additionally enhanced LC3 
conversion (Fig. 1E). These findings indicate that compound C 
increased autophagic flux, rather than merely prevented auto-
phagic proteolysis in U251 glioma cells. Accordingly, treatment 
with compound C reduced the levels of p62 (Fig. 1D), a protein 
selectively degraded by autophagy.42 Similar results were obtained 
in cell culture medium without glutamine (data not shown), thus 
eliminating the possibility that autophagy induction was medi-
ated by ammonia derived from glutaminolysis.43
Compound C-mediated autophagy is associated with down-
regulation of AMPK and Akt/mTOR signaling. To get some 
insight into the molecular mechanisms of compound C-mediated 
autophagy induction in U251 cells, we analyzed the activation 
status of the key members of autophagy-related AMPK/mTOR 
and Akt/mTOR pathways. As expected, compound C caused a 
potent downregulation of AMPK activation, almost completely 
blocking its phosphorylation after 1 h, which was accordingly 
accompanied by a marked reduction in phosphorylation of the 
AMPK target raptor (Fig. 2A). However, contrary to the role of 
raptor in mTOR inhibition, phosphorylation of mTOR, as well 
as that of the direct mTOR downstream target p70S6K, was also 
reduced by compound C (Fig. 2A). The discrepancy between 
the activation status of AMPK/raptor on one side and mTOR/
p70S6K on the other side prompted us to assess the influence of 
compound C on Akt, a well-known mTOR activator. Indeed, 
compound C in a time-dependent manner reduced the phos-
phorylation of Akt, which was almost completely abolished after 
18 h of treatment (Fig. 2A). It should be noted that the apparent 
rebound and mTOR activation at the 18th hour was not associ-
ated with the increase of S6K and Akt phosphorylation, which 
is consistent with the fact that mTOR and S6K might also be 
regulated independently of Akt and mTOR, respectively.44,45 
Interestingly, the phosphorylation of tyrosine kinase Src at 
Y418 (Y424 in mouse), which triggers PI3K activation and sub-
sequent phosphorylation of Akt,46 was also impaired in com-
pound C-exposed cells (Fig. 2A). Treatment with Akt inhibitor 
cells from apoptotic or necrotic cell death induced by various 
anticancer treatments.10
The serine/threonine kinase mammalian target of rapamy-
cin (mTOR) is a major negative regulator of autophagy.11,12 The 
phosphoinositide 3-kinase (PI3K)-activated serine/threonine 
kinase Akt phosphorylates the mTOR repressor tuberous sclerosis 
complex 2,13 thus leading to activation of mTOR and subsequent 
blockade of expression and function of autophagy-inducing Atg 
proteins.11,12 In addition to Akt, one of the main mTOR regu-
lators is AMP-activated protein kinase (AMPK), a principal 
energy-sensing intracellular enzyme activated in various cellular 
and environmental stress conditions. In response to increase in 
AMP/ATP ratio, AMPK preserves energy by switching off ATP-
requiring processes, while switching on ATP-generating catabolic 
pathways.14 AMPK maintains energy homeostasis by inducing 
autophagy and blocking protein synthesis and cell proliferation 
mainly through phosphorylation of its downstream target raptor 
and consequent inhibition of mTOR.15 In addition to a major 
role of AMPK/mTOR pathway in regulation of intracellular and 
whole body metabolism, recent findings point to its potential 
involvement in controlling proliferation, survival and death of 
cancer cells.16 Namely, pharmacological activation or overexpres-
sion of AMPK in a variety of cancer cell types caused an mTOR 
inhibition-associated cell cycle arrest and apoptotic death both in 
vitro and in vivo.17-20 On the other hand, AMPK activity in cer-
tain conditions protected normal and cancer cells from metabolic 
stress and/or chemotherapy-induced apoptosis.21-24 Autophagic 
digestion of intracellular proteins triggered by mTOR-down-
regulation in tumor cells seems to play an important role both 
in AMPK-mediated cytotoxicity25,26 and cytoprotection,27,28 the 
final outcome possibly depending on the nature of the cytotoxic 
stimulus.
Compound C (6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyr-
idin-4-ylpyrazolo[1,5-a]pyrimidine), also known as dorsomor-
phin, has recently been described as a pharmacological AMPK 
inhibitor that efficiently blocks metabolic actions of AMPK.29 In 
addition, compound C inhibited pro-apoptotic and anti-apop-
totic actions of AMPK in various experimental settings18,24,25,30-36 
and blocked AMPK-dependent autophagy in different types of 
normal and cancer cells.25,37-39 In the present study, contrary to 
expectations, we demonstrate for the first time the ability of com-
pound C to induce autophagic response in different cancer cell 
lines. The observed effect was independent of AMPK inhibition 
and mediated through suppression of Akt and subsequent down-
regulation of mTOR, ultimately leading to autophagy-dependent 
interference with compound C-induced apoptosis.
Results
Compound C induces autophagy in U251 glioma cells. In pre-
liminary experiments, we have observed that treatment of U251 
glioma cells with compound C led to accumulation of acridine 
orange-stained orange-red acidic vesicles resembling autolyso-
somes (Fig. 1A, upper part), resulting in the increase in cellu-
lar red fluorescence measured by flow cytometry (Fig. 1A, lower 
part). The quantitative analysis of acridine orange-stained U251 
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AMPK inhibition is not involved in compound C-induced 
Akt/mTOR blockade and autophagy. To investigate if the AMPK 
inhibition was involved in the observed blockade of Akt/mTOR 
signaling by compound C, we transfected U251 cells with siRNA 
directed against both α1 and α2 catalytic subunits of AMPK. 
The efficiency of siRNA-mediated AMPK downregulation was 
10-DEBC hydrochloride, PI3 kinase/Akt inhibitor LY294002 or 
mTOR inhibitor rapamycin mimicked the compound C-induced 
increase in acridine orange red/green fluorescence ratio in U251 
cells (Fig. 2B). Thus, it appears that downregulation of Src/Akt/
mTOR pathway might be responsible for compound C-mediated 
autophagy in U251 glioma cells.
Figure 1. compound c induces autophagy in U251 glioma cells. (A and B) U251 cells were incubated with or without 10 µM of compound c for  24 h (A) 
or different concentrations of compound c for the indicated time periods (B). The presence of acridine orange-stained intracellular vesicles was dem-
onstrated by fluorescent microscopy (A; upper panel) and flow cytometry, showing an increase in red-to-green (FL3/FL1) fluorescence intensity (A; low-
er panel). (B) The autophagy was quantified by calculating FL3/FL1 geomean fluorescence ratio (the data are mean + sD values from three experiments, 
*p < 0.05). (c) The TeM analysis of the compound c-treated cells (10 mM, 24 h) showing intensive vacuolization (middle panel) and autophagolysosome-
like vesicles in which cellular content is degraded (right panel). (D and e) immunoblot analysis of (D) Lc3 conversion, beclin-1 and p62 levels in U251 
cells treated with compound c (10 mM) for the indicated times or with (e)   compound c (10 mM) and/or proteolysis inhibitors bafilomycin A1 (BAF; 50 
nm), chloroquine (cQ; 50 mM) and amonium chloride (Ac; 25 mM) for 6 h (the results from one of two experiments with similar results are shown).
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and C). It therefore appears that compound C-triggered Akt/
mTOR blockade and subsequent autophagy, unlike apoptosis, 
are totally independent of AMPK inhibition. Reduction of the 
intracellular levels of ATP, a known activator of Akt,47 was also 
not responsible for the observed Akt inhibition and autophagy, as 
treatment with compound C for 6 h, when Akt suppression and 
autophagy were evident (Fig. 1D and E and Fig. 2A), completely 
failed to decrease ATP concentration in U251 cells (100 ± 18% 
vs. 131 ± 24% in control and compound C-treated cells, respec-
tively; n = 3). No cell death was observed at this time-point (data 
not shown).
Autophagy inhibition increases cytotoxicity of compound 
C. During the autophagy studies, we have consistently observed 
that a proton-pump blocker bafilomycin A1, along with an 
expected reduction in autophagosome acidification in com-
pound C-treated cells, caused a clear increase in number of cells 
displaying pyknotic (apoptotic) nuclei (Fig. 4A). This finding 
prompted us to explore if compound C-triggered autophagy 
might have a cytoprotective effect in the experimental setting 
employed. Indeed, the inhibition of autophagy by bafilomycin 
confirmed by immunoblot showing reduced levels of both total 
and phosphorylated AMPK in siRNA-transfected cells (Fig. 3A). 
Accordingly, AMPK-controlled phosphorylation of raptor was 
also reduced (Fig. 3A). However, siRNA-mediated AMPK inhi-
bition completely failed to mimic compound C-induced suppres-
sion of Akt activation, as Akt phosphorylation was unaltered in 
AMPK siRNA-transfected cells (Fig. 3A). Furthermore, in con-
trast to treatment with compound C, transfection with AMPK-
directed siRNA caused an increase in phosphorylation of both 
mTOR and its target, p70S6K (Fig. 3A). However, no significant 
change in LC3 conversion was observed (Fig. 3A), indicating that 
mTOR-repressed basal autophagy could not be further inhibited 
by additional mTOR activation. We have previously shown that 
AMPK activators metformin and AICAR reduced oxidative 
stress and apoptosis triggered by high concentration (20 μM) of 
compound C.33 However, although metformin and AICAR at 
concentrations efficient in preventing apoptosis (2 mM and 0.25 
mM, respectively) restored AMPK activation, they were unable 
to affect Akt and S6K inhibition or decrease LC3 conversion and 
intracellular acidification in compound C-treated cells (Fig. 3B 
Figure 2. compound c-mediated downregulation of AMPK/raptor and Akt/mTOR pathways and the role of Akt/mTOR blockade in autophagy induc-
tion. (A) U251 cells were treated with 10 μM of compound c for the indicated times and the activation status of AMPK/Akt/mTOR pathways was as-
sessed by immunoblotting (the results from one of two experiments with similar results are shown). (B) U251 cells were incubated for 24 h with mTOR 
inhibitor rapamycin (RAPA; 10 nM), Pi3K/Akt inhibitor LY294002 (LY; 50 μM) or 10-DeBc hydrochloride (DeBc; 20 μM) and the size of the intracellular 
acidic compartment was estimated by flow cytometric analysis of red/green (FL3/FL1) fluorescence ratio (the data are mean ± sD values from three 
experiments, *p < 0.05).
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compound C-triggered autophagic response protects U251 cells 
from concomitant induction of apoptotic death.
Compound C induces protective autophagic response in dif-
ferent cancer cell lines. We next assessed whether the autoph-
agy-inducing capacity of compound C was a unique feature of 
U251 glioma cells, or it could also be observed in other cancer 
cell lines. The latter was apparently true, as the treatment with 
compound C caused a clear dose-dependent increase in FL3/
FL1 ratio in acridine orange-stained C6 rat glioma, L929 mouse 
fibrosarcoma and B16 mouse melanoma cell lines (Fig. 5A). 
The induction of autophagy in compound C-treated L929 cells 
was further confirmed by an increase in LC3 conversion in the 
A1 or lysosomal inhibitor chloroquine (Fig. 4B, left) signifi-
cantly increased the LDH release from compound C-treated 
U251 cells (Fig. 4B, right). In accordance with the LDH release 
data, compound C alone induced only marginal DNA frag-
mentation, which was markedly augmented by pharmacologi-
cal inhibition of autophagy with bafilomycin or chloroquine 
(Fig. 4C). Of note, the autophagy blockers did not cause a sig-
nificant increase in LDH release or DNA fragmentation when 
applied alone (data not shown). Accordingly, an immunob-
lot analysis of caspase-3 cleavage fragment has demonstrated 
that bafilomycin A1 markedly increased caspase-3 activation 
induced by compound C (Fig. 4D). These data indicate that 
Figure 3. AMPK inhibition does not mediate compound c-induced Akt/mTOR blockade and autophagy. (A) The activation status of AMPK/Akt/mTOR 
pathways and Lc3 conversion were evaluated by immunoblotting in nontransfected, control siRNA-transfected and AMPK-siRNA-transfected U251 
cells 48 h after transfection. (B and c) U251 cells were pretreated for 2 h with AMPK activators metformin (MeT; 2 mM) or AicAR (0.25 mM) and then 
incubated with compound c (10 μM). The activation status of AMPK/Akt/mTOR pathways and Lc3 conversion were evaluated after 8 h (B; the data 
from one of two experiments with similar results are shown), while the accumulation of acridine orange-stained acidic vesicles was assessed by flow 
cytometry after 24 h (c; the data are mean ± sD values from three experiments).
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Discussion
The present study for the first time demonstrates the ability of 
compound C, a well-known AMPK inhibitor, to induce auto-
phagy in cancer cell lines via AMPK inhibition-independent 
downregulation of Akt/mTOR pathway. The autophagy trig-
gered by compound C apparently protected tumor cells from 
concomitant induction of apoptotic cell death.
In accordance with the key role of mTOR as a repressor of 
autophagy, downregulation of mTOR activity efficiently trig-
gered an autophagic response in mammalian cells,48,49 which has 
presence of proteolysis inhibitors (Fig. 5B), reduction of p62 lev-
els and increase in Beclin 1 expression (Fig. 5C). Similarly to 
results obtained in U251 cells, these effects were associated with 
downregulation of AMPK, Akt, p70S6K and Src phosphoryla-
tion (Fig. 5C). Finally, autophagy inhibition with bafilomycin or 
chloroquine significantly augmented LDH release in compound 
C-treated cultures of C6, L929 and B16 cells (Fig. 5D). Neither 
bafilomycin nor chloroquine significantly affected LDH release 
when applied alone (data not shown). Therefore, the ability of 
compound C to induce protective autophagic response in tumor 
cells was apparently not cell type- or species-specific.
Figure 4. inhibition of autophagy increases cytotoxicity of compound c towards U251 cells. (A) U251 cells were treated with compound c (10 μM) 
and/or autophagy inhibitor bafilomycin A1 (50 nM). After 24 h, cells were stained with acridine orange for fluorescent microscopy evaluation of the 
intracellular acidic compartment and nuclear morphology. (B and c) U251 cells were incubated for 24 h with compound c (cc; 10 μM), in the presence 
or absence of autophagy inhibitors bafilomycin A1 (BAF; 50 nm) or chloroquine (cQ; 50 μM). The presence of intracellular acidic vesicles was assessed 
by flow cytometric analysis of acridine orange-stained cells (B, left; the data are mean ± sD values from three experiments, *p < 0.05), while the cell 
death was determined by LDh release assay (B, right; the data are mean ± sD values of triplicates from a representative of three experiments, *p < 
0.05). The representative flow cytometry histograms (from one of two experiments with similar results) showing the percentage of Pi-stained cells 
with fragmented DNA (sub-G) are presented in (c). (D) U251 cells are treated as in (A) and the presence of caspase-3 cleavage fragment was assessed 
by immunoblotting.
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ability of compound C to suppress vascular endothelial growth 
factor-triggered phosphorylation of Akt in endothelial cells,56 as 
well as insulin-dependent Akt activation in skeletal muscle cells.57 
Moreover, it should be noted that compound C belongs to a pyr-
azolopirymidine class of molecules, some of which are known 
to potently reduce Akt phosphorylation through blockade of Src 
kinase family.58 Accordingly, our demonstration of the ability of 
been confirmed in the present study 
by using mTOR inhibitor rapamy-
cin. Alternatively, autophagy can be 
readily induced by interfering with 
the activation of Akt,50,51 one of the 
key upstream positive regulators of 
mTOR, as seen in our experiments 
with Akt inhibitor 10-DEBC hydro-
chloride and PI3K/Akt inhibitor 
LY294002. The induction of auto-
phagy by LY294002 might seem 
surprising, having in mind the abil-
ity of PI3K inhibitors to inhibit auto-
phagy induced by different stimuli.52 
It has been shown, however, that 
PI3K inhibitors including LY294002 
could also induce autophagy53,54 
despite being able to suppress auto-
phagic response to other stimuli. This dual role is probably medi-
ated via different temporal patterns of inhibition of class I and 
class III PI3K involved in Akt activation and autophagosome 
formation, respectively.55 Therefore, it seems conceivable to 
assume that the autophagy induction in compound C-exposed 
tumor cell lines in our study was mediated via downregulation of 
the Akt/mTOR pathway. This hypothesis is consistent with the 
Figure 5. compound c induces Akt/
mTOR blockade-dependent protec-
tive autophagy in different cancer cell 
lines. (A) L929 mouse fibrosarcoma, B16 
mouse melanoma and c6 rat glioma 
cells were incubated for 24 h with 
different concentrations of compound 
c and the presence of intracellular 
acidic vesicles was assessed by flow 
cytometric analysis of acridine orange 
red/green (FL3/FL1) fluorescence ratio 
(the data from one of two experiments 
with similar results are shown). (B) im-
munoblot analysis of Lc3 conversion 
in L929 cells treated for 6 h with com-
pound c (10 μM) and/or proteolysis 
inhibitors bafilomycin A1 (BAF; 50 nm), 
chloroquine (cQ; 50 μM) and amonium 
chloride (Ac; 25 mM). (c) immunoblot 
analysis of Lc3 conversion, Beclin1 
levels, p62 levels and AMPK/Akt/
mTOR pathways in cells treated with 
compound c (10 μM) for the indicated 
times (the results from one of two 
experiments with similar results are 
shown). (D) L929, B16 and c6 cells were 
incubated for 24 h with compound c 
(cc; 10 μM), in the presence or absence 
of autophagy inhibitors bafilomycin 
A1 (BAF; 50 nm) or chloroquine (cQ; 50 
μM) and the cell death was determined 
by LDh release assay (the data are 
mean ± sD values of triplicates from a 
representative of three experiments; 
*p < 0.05).
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induced by ionizing irradiation, hyperthermia, DNA-damaging 
agents, histone deacetylase inhibitors, imatinib, tamoxifen, TNF 
or TRAIL.27,28,65-73 Consistent with these findings, pharmacologi-
cal inhibition of autophagy in compound C-treated U251 cells 
markedly increased caspase activation and ensuing apoptotic cell 
death in our experiments. We have previously reported that cyto-
protective effects of autophagy might involve interference with 
the proapoptotic shift in the expression of Bcl-2 family proteins 
and prevention of oxidative stress.27 Similar mechanisms might 
contribute to autophagy-mediated protection from compound C, 
keeping in mind that compound C-triggered apoptosis was asso-
ciated both with the increase in Bax/Bcl-2 ratio and induction 
of oxidative stress.33 However, the exact mechanisms underlying 
the anti-apoptotic action of autophagy in compound C-exposed 
cancer cells remain to be established.
Our previous data suggest that AMPK inhibition is required, 
but not sufficient for the compound C-mediated apoptosis induc-
tion in U251 glioma cells, thus implying an AMPK-independent 
component in the observed effect.33 The inhibition of Akt, a 
known prosurvival signal,59 seems a plausible candidate for the 
putative AMPK blockade-independent proapoptotic action 
of compound C. We therefore propose a model in which both 
AMPK suppression and AMPK inhibition-independent Akt 
blockade participate in compound C-mediated apoptosis, while 
the latter mechanism and subsequent mTOR downregulation 
are responsible for the concomitant induction of autophagy that 
limits progression of apoptosis (Fig. 6). On the other hand, it 
should be noted that compound C inhibited AMPK-dependent 
autophagy in rat hepatocytes, porcine endothelial cells, human 
osteosarcoma cells, HT-29 human colon cancer cells, HeLa 
human cervical carcinoma cells and MCF-7 breast cancer cells 
exposed to starvation, avicin D, troglitazone or alisol B.25,37-39 
Accordingly, we have observed that lower concentrations of com-
pound C (≤1 μM), unlike higher concentrations (≥5 μM), can 
actually suppress AMPK-dependent autophagy in UV-irradiated 
U251 cells (Vucicevic T, et al. unpublished). While these find-
ings suggest that the effects of compound C on autophagy might 
be dose-, cell-type- and/or context-dependent, the reasons for the 
observed discrepancies are still to be fully clarified. Nevertheless, 
our data warrant caution when using compound C to inhibit 
AMPK-dependent cellular responses. In addition, they reinforce 
the concept of autophagy inhibition as a strategy for cancer cell 
sensitization and support further exploration of compound C and 
related molecules as potential anticancer agents.
Materials and Methods
Cells and cell cultures. The human glioma cell line U251 
and rat glioma cell line C6 were kindly donated by Dr. Pedro 
Tranque (Universidad de Castilla-La Mancha, Albacete, 
Spain). The mouse fibrosarcoma L929 was obtained from the 
European Collection of Animal Cell Cultures (85011425), while 
B16 mouse melanoma cell line was a kind gift from Dr. Sinisa 
Radulovic (Institute for Oncology and Radiology of Serbia, 
Belgrade, Serbia). Cells were maintained at 37°C in a humidified 
atmosphere with 5% CO
2
, in a HEPES-buffered RPMI 1640 
compound C to reduce phosphorylation of Src indicates that the 
inhibition of this tyrosine kinase might be at least partly involved 
in the observed downregulation of Akt and subsequent induction 
of autophagy.
Although AMPK and Akt activation are generally thought to 
be independently regulated,44,59 some recent data indicate a link 
between the two signaling routes. Namely, adiponectin-activated 
AMPK was responsible for Akt dephosphorylation in breast can-
cer cells,60 while, on the other hand, adiponectin- or vascular 
growth endothelial factor-mediated Akt activation in endothelial 
cells was AMPK-dependent.61 These findings suggest that in cer-
tain conditions AMPK could regulate Akt activation in a context-
dependent manner. This, however, was apparently not the case in 
our experiments, as siRNA knockdown of AMPK, while expect-
edly causing raptor inactivation and subsequent upregulation of 
mTOR/p70S6K, completely failed to affect Akt phosphoryla-
tion in U251 glioma cells. Accordingly, transfection with AMPK 
siRNA could not mimic Akt inhibition-dependent induction of 
autophagy by compound C. The finding that AMPK activators 
metformin and AICAR restored AMPK activity, but failed to 
increase Akt/S6K phosphorylation and reduce LC3 conversion in 
compound C-treated cells, further confirms that AMPK inhibi-
tion was not required for autophagy induction by compound C. 
Therefore, compound C-mediated Akt downregulation leading 
to autophagic response was completely independent of concomi-
tant AMPK suppression and able to overcome the stimulatory 
effect of AMPK/raptor blockade on the activity of mTOR. This 
is not surprising, as compound C has previously been reported to 
exert AMPK-independent biological effects, including inhibition 
of bone morphogenetic protein signaling,62 blockade of hypoxia 
inducible factor-1 activation,63 and induction of cell cycle regula-
tor p21.64
In contrast to expectations that induction of autophagy might 
be used as a “magic bullet” for the treatment of apoptosis-resistant 
cancers,9 a large body evidence supports the hypothesis that tumor 
cells in certain conditions might actually use autophagy to evade 
therapy-induced death. Accordingly, inhibition of autophagy, 
particularly at a late stage, sensitized cancer cells to apoptosis 
Figure 6. A hypothetical mechanism of signaling and apoptosis/
autophagy interactions in compound c-treated cancer cells. The down-
ward arrows denote inhibition of AMPK, Akt and mTOR. The dashed line 
indicates that the expected upregulation of mTOR by AMPK blockade is 
overcome by concomitant downregulation of mTOR via Akt blockade.
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phospho-Src (ab4816), Src (ab47405; Abcam) or p62 (647702; 
Biolegend) and peroxidase-conjugated goat anti-rabbit IgG 
(Jackson ImmunoResearch Laboratories, 111-035-003) as the 
secondary antibody, specific protein bands were visualized using 
Amersham ECL reagent (GE Healthcare, RPN2109). The levels 
of LC3-II were quantified by densitometry using ImageJ software 
and expressed relative to actin signals.
Transfection with small interfering RNA (siRNA). The 
siRNA targeting human AMPKα1/2 and scrambled control 
siRNA were obtained from Santa Cruz Biotechnology (sc-45312). 
Subconfluent U251 cells in 90 mm Petri dishes were transfected 
with AMPK and control siRNA according to the manufacturer’s 
protocol. Cells were allowed to grow 48 h following transfection 
and then were lysed for western blot analysis.
Determination of cell viability and apoptosis. The release 
of cytosolic lactate dehydrogenase (LDH) into the supernatant 
of cultured cells indicates the loss of membrane integrity that 
occurs in dead cells. The assay was performed exactly as pre-
viously described74 and the pyruvate-mediated conversion of 
2,4-dinitrophenylhydrazine into visible hydrazone precipitate, 
correlating with the extent of cell death, was measured at 492 
nm. The results were presented as % cytotoxicity according to 
the formula: 100 x (a - b)/(c - b), where a, b and c are the absor-
bances of the experimental sample, negative control (cell culture 
medium without cells) and positive control (cells lysed with 3% 
Triton-X100), respectively. DNA fragmentation as a marker of 
apoptosis was assessed by flow cytometric analysis of cells stained 
with DNA-binding dye propidium iodide. Briefly, cells were 
fixed in 70% ethanol and then incubated with 50 μg/ml RNAse 
(Sigma-Aldrich, R6513) and 40 μg/ml propidium iodide (Sigma-
Aldrich, P4170) for 30 min at 37°C in the dark. Red fluorescence 
was analyzed at FACSCalibur flow cytometer, using FL2-W vs. 
FL2-A dot plot to exclude cell aggregates. The number of hypo-




 compartment was analyzed 
using Cell Quest Pro software.
Intracellular ATP measurement. The concentration of 
intracellular ATP was determined using a luminescence-based 
ATP detection assay system (ATPLite, Perkin Elmer, 6016943) 
according to the manufacturer’s instructions.
Statistical analysis. The statistical significance of the differ-
ences between treatments was assessed using one-way ANOVA 
followed by Student-Neuman-Keuls test for multiple compari-
sons. The value of p < 0.05 was considered significant.
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cell culture medium with L-glutamine (Sigma-Aldrich, R7388) 
supplemented with 5% fetal bovine serum (Sigma-Aldrich, 
F2442), 1 mM sodium pyruvate (Sigma-Aldrich, S8636) and 10 
ml/L penicillin/streptomycin (Sigma-Aldrich, P0781). The cells 
were incubated in 96-well flat bottom plates (1 x 104 cells/well) 
for the cell viability assays, 24-well plates (1 x 105 cells/well) for 
the flow cytometry analysis or 90 mm Petri dishes (2 x 106 cells) 
for the western blotting. Cells were rested for 24 h and then 
treated with compound C (Sigma-Aldrich, P5499) and/or Akt 
inhibitor 10-DEBC hydrochloride (Tocris Bioscience, 2558), 
PI3K inhibitor LY294002 (Tocris Bioscience, 1130), mTOR 
inhibitor rapamycin (Sigma-Aldrich, R8781), AMPK activa-
tors metformin hydrochloride (Gluformin®, Hemofarm) and 
aminoimidazole carboxamide ribonucleotide (AICAR; Sigma-
Aldrich, A9978) or lysosomal inhibitors bafilomycin A1 (Sigma-
Aldrich, 11711), ammonium chloride (Sigma-Aldrich, A0171) 
and chloroquine (Sigma-Aldrich, C6628). The incubation times 
and concentrations of agents are stated in figure legends and/or 
figures.
Autophagy detection by acridine orange staining and trans-
mission electron microscopy (TEM). The acidic intracellular 
compartments were visualized by supravital acridine orange stain-
ing. After incubation, cells were washed with phosphate-buffered 
saline and stained with 1 μM acridine orange (Sigma-Aldrich, 
318337) for 15 min at 37°C. Subsequently, cells were washed and 
analyzed under the inverted fluorescent microscope. Depending 
on their acidity, autophagic lysosomes appeared as orange/red 
fluorescent cytoplasmic vesicles, while nuclei were stained green. 
Alternatively, acridine orange-stained cells were trypsinized, 
washed and analyzed on a FACSCalibur flow cytometer (Becton, 
Dickinson and Company) using Cell Quest Pro software. The 
autophagy was quantified as a ratio between geomean fluores-
cence intensity of red vs. green fluorescence (FL3/FL1). For the 
TEM analysis, trypsinized cells were fixed with 2.5% glutaralde-
hyde in phosphate-buffered saline, followed by 2% OsO
4
. After 
dehydration, thin sections were stained with uranyl acetate and 
lead citrate for observation under a Morgagni 268(D) electron 
microscope (FEI).
Western blot analysis of autophagy, AMPK/Akt/mTOR 
signaling and caspase-3 activation. Cells were lysed in lysis 
buffer (30 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40) 
containing 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich, 
P7626) and protease inhibitor cocktail (Sigma-Aldrich, P8340) 
on ice for 30 min, centrifuged at 14,000 g for 15 min at 4°C, and 
the supernatants were collected as the cell lysates. Equal amounts 
of protein from each sample was separated by SDS-PAGE on 
6–15% gels and transferred to nitrocellulose membranes (Bio-
Rad, 162-0115). Following incubation with primary antibodies 
against LC3B (2775), phospho-AMPK (2535), AMPK (2603), 
phospho-Akt (4058), Akt (9272), phospho-mTOR (2971), 
mTOR (2983), phospho-raptor (2083), raptor (2280), phospho-
p70S6K (9205), p70S6K (2708), Beclin 1 (3495), caspase-3 cleav-
age fragment (9664), actin (4968; Cell Signaling Technology), 
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